414 related articles for article (PubMed ID: 19333979)
1. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
López-Longo FJ; Oliver-Miñarro D; de la Torre I; González-Díaz de Rábago E; Sánchez-Ramón S; Rodríguez-Mahou M; Paravisini A; Monteagudo I; González CM; García-Castro M; Casas MD; Carreño L
Arthritis Rheum; 2009 Apr; 61(4):419-24. PubMed ID: 19333979
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis.
Cha S; Choi CB; Han TU; Kang CP; Kang C; Bae SC
Arthritis Rheum; 2007 May; 56(5):1454-63. PubMed ID: 17469103
[TBL] [Abstract][Full Text] [Related]
3. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?
López-Longo FJ; Sánchez-Ramón S; Carreño L
Drug News Perspect; 2009 Nov; 22(9):543-8. PubMed ID: 20072731
[TBL] [Abstract][Full Text] [Related]
4. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides.
Pedersen M; Jacobsen S; Klarlund M; Pedersen BV; Wiik A; Wohlfahrt J; Frisch M
Arthritis Res Ther; 2006; 8(4):R133. PubMed ID: 16872514
[TBL] [Abstract][Full Text] [Related]
5. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
[TBL] [Abstract][Full Text] [Related]
6. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
8. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
[TBL] [Abstract][Full Text] [Related]
9. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
van der Helm-van Mil AH; Verpoort KN; le Cessie S; Huizinga TW; de Vries RR; Toes RE
Arthritis Rheum; 2007 Feb; 56(2):425-32. PubMed ID: 17265477
[TBL] [Abstract][Full Text] [Related]
10. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
Panchagnula R; Rajiv SR; Prakash J; Chandrashekara S; Suresh KP
J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
[TBL] [Abstract][Full Text] [Related]
11. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
[TBL] [Abstract][Full Text] [Related]
12. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
[TBL] [Abstract][Full Text] [Related]
13. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark.
Pedersen M; Jacobsen S; Garred P; Madsen HO; Klarlund M; Svejgaard A; Pedersen BV; Wohlfahrt J; Frisch M
Arthritis Rheum; 2007 May; 56(5):1446-53. PubMed ID: 17469102
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
Sihvonen S; Korpela M; Mustila A; Mustonen J
J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
[TBL] [Abstract][Full Text] [Related]
16. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.
Bos WH; Ursum J; de Vries N; Bartelds GM; Wolbink GJ; Nurmohamed MT; van der Horst-Bruinsma IE; van de Stadt RJ; Crusius JB; Tak PP; Dijkmans BA; van Schaardenburg D
Ann Rheum Dis; 2008 Sep; 67(9):1347-50. PubMed ID: 18388157
[TBL] [Abstract][Full Text] [Related]
17. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.
Huizinga TW; Amos CI; van der Helm-van Mil AH; Chen W; van Gaalen FA; Jawaheer D; Schreuder GM; Wener M; Breedveld FC; Ahmad N; Lum RF; de Vries RR; Gregersen PK; Toes RE; Criswell LA
Arthritis Rheum; 2005 Nov; 52(11):3433-8. PubMed ID: 16255021
[TBL] [Abstract][Full Text] [Related]
18. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
[TBL] [Abstract][Full Text] [Related]
19. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
[TBL] [Abstract][Full Text] [Related]
20. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis.
Inui N; Enomoto N; Suda T; Kageyama Y; Watanabe H; Chida K
Clin Biochem; 2008 Sep; 41(13):1074-7. PubMed ID: 18638466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
